Circulating cell‐free DNA in liver transplantation: A pre‐ and post‐transplant biomarker of graft dysfunction
Artificial Organs · 2025-04 · 49 (4) · 649-662
DOI: 10.1111/aor.14910 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Artificial Organs, online erschienen am 18.11.2024. Verfasst von Monica Sorbini und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Liver Transplantation, Cell-Free Nucleic Acids, Graft Rejection, Primary Graft Dysfunction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Liver transplantation (LT) is still limited by organ shortage and post‐transplant monitoring issues. While machine perfusion techniques allow for improving organ preservation, biomarkers like donor‐derived cell‐free DNA (dd‐cfDNA) and mitochondrial cfDNA (mt‐cfDNA) may provide insights into graft injury and viability pre‐ and post‐LT.
Methods
A prospective observational cohort study was conducted on LT recipients ( n = 45) to evaluate dd‐cfDNA as a biomarker of graft dysfunction during the first 6 months after LT. Dd‐cfDNA was quantified on blood samples collected pre‐LT and post‐LT using droplet digital PCR. In livers undergoing dual hypothermic oxygenated machine perfusion (D‐HOPE), total cfDNA and mt‐cfDNA levels were measured on perfusate samples collected at 30‐min intervals. Correlations with graft function and clinical outcomes were assessed.
Results
Dd‐cfDNA levels peaked post‐LT and correlated with transaminase levels and histological injury severity. The longitudinal assessment showed that postoperative complications and rejection were associated with an increase in dd‐cfDNA levels. Mt‐cfDNA levels in D‐HOPE perfusate correlated with graft function parameters post‐LT and were higher in patients with early allograft dysfunction and severe complications.
Conclusions
This study confirms dd‐cfDNA as a marker of graft injury after LT and suggests that perfusate mt‐cfDNA levels during D‐HOPE correlate with graft function and post‐transplant clinical outcome. Integration of these tests into clinical practice may improve transplant management and viability assessment during hypothermic perfusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, University of Turin, Turin, Italy.
- General Surgery 2U-Liver Transplant Center, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
- Immunogenetics and Transplant Biology Service, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
- Pathology Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
Zitieren
APA
Sorbini, M., Carradori, T., Patrono, D., Togliatto, G., Caorsi, C., Vaisitti, T., Mansouri, M., Delsedime, L., Vissio, E., De Stefano, N., Papotti, M., Amoroso, A., Romagnoli, R., & Deaglio, S. (2025). Circulating cell‐free DNA in liver transplantation: A pre‐ and post‐transplant biomarker of graft dysfunction. Artificial Organs, 49(4), 649-662. https://doi.org/10.1111/aor.14910
Vancouver
Sorbini M, Carradori T, Patrono D, Togliatto G, Caorsi C, Vaisitti T, et al. Circulating cell‐free DNA in liver transplantation: A pre‐ and post‐transplant biomarker of graft dysfunction. Artificial Organs. 2025;49(4):649-662. doi:10.1111/aor.14910
BibTeX
@article{Sorbini2025,
author = {Sorbini, Monica and Carradori, Tullia and Patrono, Damiano and Togliatto, Gabriele and Caorsi, Cristiana and Vaisitti, Tiziana and Mansouri, Morteza and Delsedime, Luisa and Vissio, Elena and De Stefano, Nicola and Papotti, Mauro and Amoroso, Antonio and Romagnoli, Renato and Deaglio, Silvia},
title = {Circulating cell‐free DNA in liver transplantation: A pre‐ and post‐transplant biomarker of graft dysfunction},
journal = {Artificial Organs},
year = {2025},
volume = {49},
number = {4},
pages = {649--662},
doi = {10.1111/aor.14910}
}
EUVIMED